CRO partners with humanized model developer to advance liver disease research
Seventh Wave Laboratories is a consulting-based contract research organization (CRO) located in Maryland Heights, Mo.
The company provides services for discovery and preclinical drug development, including PK/ADME, bioanalysis, toxicology and pathology services.
Through the recently announced partnership, the CRO will provide services related to hepatitis B virus and C virus pharmacology studies using the Yecuris liver humanized FRG KO model.
Seventh Wave will also provide toxicology, metabolism and other pharmacology services using models developed by Yecuris Corporation.
Portland, OR-based Yecuris was founded in 2007 to commercialize the FRG KO mouse technology and has been validating viremic and gene expression models for more than a year with Seventh Wave.
"Both companies are committed to supporting the partnership as long as it makes sense for our clients. In our pre-launch period, we’ve successfully supported a number of client-sponsored studies, and we believe there is a long future ahead with this partnership," Joe Flynn, Chief Commercial Officer at Seventh Wave, told Outsourcing-Pharma.com.
"Both Seventh Wave and Yecuris have invested significantly in R&D to develop and validate this model — we’re past the theoretical stage and have proven the concept internally and also with client-sponsored studies," Flynn added. "We’ve also spent a great deal of time with prospective clients in the pre-launch period to really understand what they are looking for in terms of study design and key endpoints."
